Joshua Yarrow
Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Injuries | 18 | 2026 | 240 | 8.020 |
Why?
| | Testosterone | 28 | 2019 | 419 | 5.770 |
Why?
| | Bone and Bones | 12 | 2024 | 314 | 3.550 |
Why?
| | Muscular Atrophy | 5 | 2026 | 89 | 2.890 |
Why?
| | Muscle, Skeletal | 22 | 2026 | 1795 | 2.700 |
Why?
| | Androgens | 14 | 2018 | 186 | 1.910 |
Why?
| | Rats, Sprague-Dawley | 16 | 2026 | 2527 | 1.900 |
Why?
| | Osteogenesis | 3 | 2024 | 208 | 1.830 |
Why?
| | Physical Conditioning, Animal | 5 | 2025 | 243 | 1.560 |
Why?
| | Rats | 30 | 2026 | 5597 | 1.520 |
Why?
| | Bone Remodeling | 5 | 2026 | 71 | 1.490 |
Why?
| | Dihydrotestosterone | 6 | 2015 | 42 | 1.440 |
Why?
| | Trenbolone Acetate | 8 | 2018 | 9 | 1.420 |
Why?
| | Bone Resorption | 3 | 2018 | 80 | 1.080 |
Why?
| | Recovery of Function | 2 | 2024 | 707 | 1.080 |
Why?
| | Osteoporosis | 5 | 2015 | 236 | 1.050 |
Why?
| | Prostate | 4 | 2017 | 158 | 0.970 |
Why?
| | Bone Density | 10 | 2025 | 482 | 0.950 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2018 | 142 | 0.940 |
Why?
| | X-Ray Microtomography | 8 | 2026 | 107 | 0.940 |
Why?
| | Finasteride | 5 | 2017 | 33 | 0.850 |
Why?
| | Hindlimb Suspension | 2 | 2014 | 11 | 0.810 |
Why?
| | Estradiol | 6 | 2018 | 533 | 0.810 |
Why?
| | Animals | 41 | 2026 | 38058 | 0.800 |
Why?
| | Locomotion | 1 | 2024 | 105 | 0.790 |
Why?
| | Cancellous Bone | 3 | 2024 | 22 | 0.790 |
Why?
| | Fibrosis | 2 | 2024 | 548 | 0.730 |
Why?
| | Hormone Replacement Therapy | 4 | 2018 | 106 | 0.720 |
Why?
| | Estrogens | 4 | 2018 | 380 | 0.700 |
Why?
| | Exercise | 6 | 2022 | 2201 | 0.660 |
Why?
| | Hindlimb | 3 | 2026 | 131 | 0.660 |
Why?
| | Ovariectomy | 3 | 2018 | 162 | 0.660 |
Why?
| | Anabolic Agents | 5 | 2016 | 12 | 0.640 |
Why?
| | Male | 50 | 2026 | 72315 | 0.620 |
Why?
| | Orchiectomy | 9 | 2018 | 74 | 0.620 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 170 | 0.610 |
Why?
| | Relaxin | 1 | 2019 | 18 | 0.600 |
Why?
| | Periodontitis | 4 | 2021 | 54 | 0.600 |
Why?
| | Skull Fractures | 1 | 2019 | 35 | 0.590 |
Why?
| | Physical Therapy Modalities | 1 | 2022 | 332 | 0.560 |
Why?
| | Neuromuscular Junction | 1 | 2018 | 65 | 0.540 |
Why?
| | Hypertriglyceridemia | 1 | 2018 | 44 | 0.540 |
Why?
| | Muscle Weakness | 1 | 2018 | 92 | 0.520 |
Why?
| | Adiponectin | 2 | 2024 | 244 | 0.510 |
Why?
| | Arthritis | 1 | 2018 | 96 | 0.510 |
Why?
| | Cholestenone 5 alpha-Reductase | 2 | 2015 | 3 | 0.490 |
Why?
| | Rats, Inbred F344 | 10 | 2018 | 268 | 0.480 |
Why?
| | Bisphosphonate-Associated Osteonecrosis of the Jaw | 3 | 2021 | 6 | 0.470 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 529 | 0.470 |
Why?
| | Disease Models, Animal | 7 | 2026 | 4557 | 0.460 |
Why?
| | Diet, High-Fat | 2 | 2021 | 261 | 0.460 |
Why?
| | Fructose | 1 | 2016 | 130 | 0.450 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 340 | 0.450 |
Why?
| | Bicycling | 2 | 2025 | 120 | 0.410 |
Why?
| | Muscles | 2 | 2014 | 333 | 0.400 |
Why?
| | Sarcopenia | 1 | 2015 | 91 | 0.400 |
Why?
| | Muscle Strength | 5 | 2018 | 330 | 0.390 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 200 | 0.390 |
Why?
| | Hypogonadism | 4 | 2015 | 90 | 0.380 |
Why?
| | Adaptation, Physiological | 2 | 2024 | 570 | 0.360 |
Why?
| | Human Growth Hormone | 2 | 2012 | 46 | 0.360 |
Why?
| | Resistance Training | 2 | 2012 | 182 | 0.330 |
Why?
| | Osteonecrosis | 2 | 2021 | 23 | 0.320 |
Why?
| | Feeding Behavior | 1 | 2016 | 684 | 0.310 |
Why?
| | Bone Diseases, Metabolic | 2 | 2021 | 56 | 0.310 |
Why?
| | Lactic Acid | 2 | 2008 | 302 | 0.300 |
Why?
| | Exercise Therapy | 4 | 2024 | 473 | 0.300 |
Why?
| | Aromatase | 3 | 2015 | 32 | 0.300 |
Why?
| | Physical Endurance | 2 | 2010 | 278 | 0.300 |
Why?
| | Hemoglobins | 2 | 2012 | 384 | 0.300 |
Why?
| | Bone Density Conservation Agents | 2 | 2021 | 81 | 0.300 |
Why?
| | Hypertension | 1 | 2018 | 1263 | 0.300 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2010 | 148 | 0.290 |
Why?
| | Physical Education and Training | 1 | 2008 | 71 | 0.280 |
Why?
| | Femur | 3 | 2024 | 250 | 0.270 |
Why?
| | Aging | 2 | 2015 | 1966 | 0.260 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 31 | 0.260 |
Why?
| | Weight Lifting | 1 | 2007 | 32 | 0.260 |
Why?
| | Tibia | 2 | 2024 | 176 | 0.250 |
Why?
| | Receptors, Androgen | 4 | 2018 | 153 | 0.250 |
Why?
| | 5-alpha Reductase Inhibitors | 2 | 2017 | 16 | 0.240 |
Why?
| | Adiposity | 1 | 2011 | 543 | 0.230 |
Why?
| | Genetic Markers | 2 | 2018 | 331 | 0.230 |
Why?
| | Atrophy | 2 | 2018 | 201 | 0.230 |
Why?
| | Tibial Meniscus Injuries | 1 | 2026 | 62 | 0.230 |
Why?
| | Adipose Tissue | 2 | 2021 | 652 | 0.230 |
Why?
| | Regional Blood Flow | 2 | 2026 | 514 | 0.220 |
Why?
| | Organ Size | 5 | 2018 | 463 | 0.220 |
Why?
| | Knee Injuries | 1 | 2026 | 122 | 0.220 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 125 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 1720 | 0.220 |
Why?
| | Humans | 28 | 2022 | 144759 | 0.210 |
Why?
| | Rats, Inbred Lew | 2 | 2026 | 103 | 0.210 |
Why?
| | Epiphyses | 1 | 2024 | 25 | 0.210 |
Why?
| | Obesity | 1 | 2018 | 3077 | 0.210 |
Why?
| | Osteoarthritis | 1 | 2026 | 196 | 0.200 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2026 | 216 | 0.200 |
Why?
| | Mice, Inbred C57BL | 3 | 2024 | 5992 | 0.190 |
Why?
| | Osteoarthritis, Knee | 1 | 2026 | 279 | 0.190 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 2168 | 0.180 |
Why?
| | Body Weight | 4 | 2016 | 976 | 0.170 |
Why?
| | Regeneration | 2 | 2021 | 197 | 0.170 |
Why?
| | Perfusion | 1 | 2022 | 250 | 0.170 |
Why?
| | Cachexia | 1 | 2021 | 75 | 0.160 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2020 | 5 | 0.160 |
Why?
| | Contusions | 1 | 2020 | 25 | 0.160 |
Why?
| | Chemokine CXCL1 | 1 | 2020 | 76 | 0.160 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 188 | 0.150 |
Why?
| | Infusions, Subcutaneous | 1 | 2019 | 24 | 0.150 |
Why?
| | Biomechanical Phenomena | 3 | 2025 | 842 | 0.150 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 1047 | 0.140 |
Why?
| | Pressure Ulcer | 1 | 2019 | 43 | 0.140 |
Why?
| | Cortical Bone | 1 | 2018 | 15 | 0.140 |
Why?
| | Signal Transduction | 5 | 2021 | 5226 | 0.140 |
Why?
| | Post-Concussion Syndrome | 1 | 2021 | 184 | 0.140 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.140 |
Why?
| | Drug Administration Routes | 1 | 2018 | 42 | 0.140 |
Why?
| | Long-Term Care | 1 | 2019 | 117 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2021 | 266 | 0.140 |
Why?
| | Hypothalamus | 1 | 2018 | 153 | 0.130 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 291 | 0.130 |
Why?
| | Multimorbidity | 1 | 2018 | 63 | 0.130 |
Why?
| | Transcriptome | 1 | 2024 | 1045 | 0.130 |
Why?
| | Growth Hormone | 2 | 2008 | 92 | 0.130 |
Why?
| | Mice, Knockout | 1 | 2024 | 3121 | 0.130 |
Why?
| | Hand Strength | 1 | 2018 | 144 | 0.130 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1782 | 0.130 |
Why?
| | Leptin | 1 | 2018 | 245 | 0.130 |
Why?
| | Biomarkers | 4 | 2016 | 4271 | 0.130 |
Why?
| | Up-Regulation | 1 | 2020 | 851 | 0.120 |
Why?
| | Prevalence | 3 | 2019 | 2834 | 0.120 |
Why?
| | Nutrition Surveys | 1 | 2018 | 282 | 0.120 |
Why?
| | Myostatin | 1 | 2016 | 24 | 0.120 |
Why?
| | Skin | 1 | 2021 | 755 | 0.120 |
Why?
| | Sigmodontinae | 3 | 2021 | 4 | 0.120 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 210 | 0.120 |
Why?
| | Satellite Cells, Skeletal Muscle | 1 | 2016 | 32 | 0.120 |
Why?
| | Placebos | 2 | 2014 | 192 | 0.120 |
Why?
| | Eating | 1 | 2018 | 389 | 0.120 |
Why?
| | Motor Neurons | 1 | 2018 | 234 | 0.120 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1370 | 0.120 |
Why?
| | Adipogenesis | 1 | 2016 | 57 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1217 | 0.110 |
Why?
| | Pilot Projects | 2 | 2011 | 1886 | 0.110 |
Why?
| | Body Composition | 2 | 2016 | 706 | 0.110 |
Why?
| | Casts, Surgical | 1 | 2014 | 35 | 0.110 |
Why?
| | Injections | 1 | 2015 | 196 | 0.110 |
Why?
| | Athletic Injuries | 1 | 2021 | 569 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1539 | 0.110 |
Why?
| | Injections, Intramuscular | 1 | 2014 | 141 | 0.100 |
Why?
| | Bone Marrow | 1 | 2016 | 304 | 0.100 |
Why?
| | Adult | 7 | 2021 | 40449 | 0.100 |
Why?
| | Aromatase Inhibitors | 1 | 2014 | 75 | 0.100 |
Why?
| | Random Allocation | 1 | 2015 | 363 | 0.100 |
Why?
| | Adipocytes | 1 | 2016 | 223 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2020 | 2832 | 0.100 |
Why?
| | Tandem Mass Spectrometry | 2 | 2017 | 576 | 0.100 |
Why?
| | Aged | 8 | 2021 | 25913 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 2027 | 0.100 |
Why?
| | Nitriles | 1 | 2014 | 205 | 0.100 |
Why?
| | False Positive Reactions | 1 | 2013 | 121 | 0.100 |
Why?
| | Brain Concussion | 1 | 2021 | 640 | 0.100 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 919 | 0.100 |
Why?
| | Triazoles | 1 | 2014 | 184 | 0.100 |
Why?
| | Reference Standards | 1 | 2013 | 177 | 0.100 |
Why?
| | Minerals | 1 | 2012 | 47 | 0.090 |
Why?
| | Liver | 1 | 2021 | 1887 | 0.090 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 40 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2014 | 2029 | 0.090 |
Why?
| | Iron | 1 | 2014 | 359 | 0.090 |
Why?
| | Absorptiometry, Photon | 1 | 2012 | 276 | 0.090 |
Why?
| | Middle Aged | 7 | 2021 | 35875 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2925 | 0.080 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2010 | 58 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3333 | 0.080 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2010 | 7 | 0.080 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 194 | 0.080 |
Why?
| | Organ Specificity | 1 | 2011 | 312 | 0.080 |
Why?
| | Female | 9 | 2025 | 78271 | 0.080 |
Why?
| | Diphosphonates | 2 | 2021 | 68 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2878 | 0.080 |
Why?
| | Body Mass Index | 1 | 2018 | 2438 | 0.070 |
Why?
| | Mice | 3 | 2024 | 18339 | 0.070 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2009 | 137 | 0.070 |
Why?
| | Osteocalcin | 1 | 2008 | 38 | 0.070 |
Why?
| | Molecular Structure | 1 | 2010 | 499 | 0.070 |
Why?
| | Erythrocytes | 1 | 2014 | 757 | 0.070 |
Why?
| | Tensile Strength | 1 | 2008 | 96 | 0.070 |
Why?
| | Myocardial Ischemia | 1 | 2009 | 285 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1496 | 0.070 |
Why?
| | Amino Acids | 2 | 2008 | 521 | 0.070 |
Why?
| | Rest | 1 | 2008 | 124 | 0.060 |
Why?
| | Physical Exertion | 1 | 2008 | 207 | 0.060 |
Why?
| | Florida | 1 | 2007 | 117 | 0.060 |
Why?
| | Biological Availability | 1 | 2007 | 142 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2015 | 11679 | 0.060 |
Why?
| | Creatinine | 1 | 2008 | 506 | 0.060 |
Why?
| | Sex Factors | 1 | 2012 | 2112 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2730 | 0.060 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2008 | 192 | 0.060 |
Why?
| | Cognition | 1 | 2014 | 1266 | 0.060 |
Why?
| | Heart | 1 | 2009 | 636 | 0.060 |
Why?
| | Aged, 80 and over | 2 | 2015 | 8265 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2608 | 0.050 |
Why?
| | Muscle Contraction | 1 | 2008 | 429 | 0.050 |
Why?
| | Electric Stimulation | 1 | 2025 | 276 | 0.050 |
Why?
| | Veterans | 1 | 2017 | 1603 | 0.050 |
Why?
| | Kidney | 2 | 2012 | 1495 | 0.050 |
Why?
| | Exercise Test | 1 | 2007 | 634 | 0.050 |
Why?
| | Murinae | 1 | 2021 | 6 | 0.040 |
Why?
| | Vasodilation | 1 | 2024 | 523 | 0.040 |
Why?
| | Jaw | 1 | 2021 | 27 | 0.040 |
Why?
| | Cicatrix | 1 | 2021 | 69 | 0.040 |
Why?
| | United States | 1 | 2018 | 15966 | 0.040 |
Why?
| | Risk Factors | 1 | 2014 | 10779 | 0.040 |
Why?
| | Caseins | 1 | 2019 | 20 | 0.040 |
Why?
| | Quadriplegia | 1 | 2019 | 14 | 0.040 |
Why?
| | Sucrose | 1 | 2019 | 112 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2018 | 18 | 0.040 |
Why?
| | Appetite Depressants | 1 | 2018 | 19 | 0.040 |
Why?
| | Paralysis | 1 | 2019 | 67 | 0.030 |
Why?
| | Wnt-5a Protein | 1 | 2018 | 24 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1382 | 0.030 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 214 | 0.030 |
Why?
| | Cell Enlargement | 1 | 2016 | 8 | 0.030 |
Why?
| | Activin Receptors, Type II | 1 | 2016 | 12 | 0.030 |
Why?
| | Smad3 Protein | 1 | 2016 | 43 | 0.030 |
Why?
| | Smad2 Protein | 1 | 2016 | 37 | 0.030 |
Why?
| | Cell Count | 1 | 2016 | 320 | 0.030 |
Why?
| | Testis | 1 | 2016 | 163 | 0.030 |
Why?
| | Ribosomal Proteins | 1 | 2016 | 91 | 0.030 |
Why?
| | RNA, Ribosomal | 1 | 2016 | 168 | 0.030 |
Why?
| | Muscle Development | 1 | 2016 | 116 | 0.030 |
Why?
| | Heptanoates | 1 | 2014 | 2 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2014 | 21 | 0.030 |
Why?
| | CCN Intercellular Signaling Proteins | 1 | 2014 | 5 | 0.030 |
Why?
| | Transferrin | 1 | 2014 | 50 | 0.030 |
Why?
| | Ribosomes | 1 | 2016 | 191 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 69 | 0.030 |
Why?
| | Muscle Proteins | 1 | 2016 | 244 | 0.030 |
Why?
| | Anthropometry | 1 | 2014 | 200 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1658 | 0.030 |
Why?
| | Myosins | 1 | 2014 | 136 | 0.030 |
Why?
| | Drug Interactions | 1 | 2014 | 398 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2018 | 790 | 0.020 |
Why?
| | Receptors, Glucocorticoid | 1 | 2014 | 138 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2021 | 1241 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2014 | 233 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2014 | 454 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 851 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 750 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2014 | 437 | 0.020 |
Why?
| | Time Factors | 2 | 2014 | 7173 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2882 | 0.020 |
Why?
| | Isotonic Contraction | 1 | 2009 | 1 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2009 | 115 | 0.020 |
Why?
| | Young Adult | 2 | 2021 | 14105 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2016 | 2050 | 0.020 |
Why?
| | Adolescent | 1 | 2007 | 22428 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2009 | 421 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1306 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 402 | 0.010 |
Why?
| | Databases, Factual | 1 | 2012 | 1486 | 0.010 |
Why?
| | Cohort Studies | 1 | 2017 | 5960 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2021 | 17066 | 0.010 |
Why?
|
|
Yarrow's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|